Novartis commits $1bn for ex-US rights to Ophthotech AMD drug
This article was originally published in Scrip
Executive Summary
Ophthotech will almost double its cash balance with a $200m upfront payment and $130m in near-term milestone fees under a deal worth up to $1.03bn plus royalties that gives Novartis ex-US rights to Fovista for wet age-related macular degeneration (AMD).
You may also be interested in...
Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
Fovista AMD Failure Puts Eylea In The Clear, Blurs Anti-PDGF Prospects
The failure of two Phase III Fovista and Lucentis combination trials in treating wet AMD probably lifts the threat of shifts towards PDGF/VEGF combinations and thereby leaves Regeneron's Eylea sales in the clear.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.